Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Alder pollen protein, primarily Aln g 1, is a major allergen belonging to the PR-10 protein family. It triggers allergic reactions such as rhinitis and conjunctivitis. Aln g 1 exhibits cross-reactivity with other tree pollens due to shared IgE-binding epitopes. It is considered a therapeutic target for potential immunotherapy due to the possibility of developing hypoallergenic variants.
Site-directed mutagenesis to reduce IgE binding and lipid ligand affinity for potential immunotherapy.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Alder Pollen Protein (None).